Comparing the current results to its competitors, Avricore Health Inc reported Revenue increase in the 4 quarter 2024 by 79.01 % year on year. The sales growth was above Avricore Health Inc 's competitors' average revenue growth of 30.65 %, achieved in the same quarter.
Avricore Health Inc 's Comment on Competition and Industry Peers
The Company faces potential competition from alternative point-of-care testing (POCT) platforms. While current competition is limited, new competitors may emerge offering alternative platforms. The Company may compete with firms that are established in certain markets or have greater financial resources. There is also a risk that the Company's intellectual property could infringe on the rights of other companies, which could result in reduced revenues, sanctions, product withdrawal, and legal costs. As of the time of writing, the Company is not aware of any infringement claims against its products or processes.
Audentes Therapeutics Inc is a biotechnology company focused on developing and commercializing innovative gene therapies for serious rare diseases. Their business model revolves around conducting extensive research and development to design and produce these gene therapies. They then collaborate with healthcare providers and regulatory bodies to gain necessary approvals and commercialize their therapies, aiming to provide effective treatments for patients suffering from rare diseases.
Sarepta Therapeutics Inc's business model centers around the research, development, and commercialization of innovative genetic medicines for rare diseases, with a particular focus on Duchenne muscular dystrophy (DMD).
Biolargo Inc is a company that focuses on developing sustainable technologies and products to address issues related to water and air quality. Their business model involves licensing and selling their innovative technologies, while also collaborating with partners to commercialize and distribute their products worldwide.
Fulgent Genetics Inc is a genetic testing company that offers comprehensive, flexible, and affordable genetic testing solutions for various applications, including clinical diagnostics, carrier screening, and genetic research.
Sources:
Avricore Health Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Avricore Health Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
